This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

Doron Therapeutics


Doron Therapeutics Inc. was formed in February 2023 and is fully operated in Chapel Hill, NC, USA. Doron is a management-led spinout and licensed all key rights and interest in MOTYS™ – a phase-3 ready biologic injectable drug product to treat knee osteoarthritis (OA) from Bioventus Inc, an NC-based publicly traded medical device orthopedics company on June 2, 2023. The company is currently raising its first private investment funding round (Series A) of $25M to fund a pivotal phase 3 study. MOTYS™ is eligible for Regenerative Medicine Advanced Therapy (RMAT) designation and will target knee OA (competing and potentially replacing millions of corticosteroid and hyaluronic acid (HA) injections each year). Osteoarthritis (OA) is the second most costly health condition treated in US hospitals and is also a major contributor to the current opioid epidemic. It is the fastest growing cause of disability, and we have a 50% lifetime risk of developing the disease. MOTYS™ was developed as a key pipeline product at Bioventus but due to financial constraints, the company announced publicly plans to divest the asset - key management left to start Doron to continue the development of this promising asset. Effective and long lasting, MOTYS™ is intended to address a critical gap in the current standard of care between corticosteroids/hyaluronic acid (HA) injections (associated with safety and efficacy concerns, respectively) and knee replacement (highly invasive, long recovery, costly surgery). Our product has a conservatively estimated revenue opportunity of >$1B/year in the US alone, with the future opportunity to develop for additional OUS markets as well as other indications (proof-of-concept) established for Hip OA, tendonitis and degenerative disc disease (DDD).